The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome

摘要: Objective To investigate whether the administration of long-lasting dopaminergic drug, cabergoline, improves endocrine and clinical features women with polycystic ovary syndrome (PCOS). Patients Twenty-nine participated in study: 14 endocrinologic PCOS 15 age- weight-matched normal cycling women. Each subject was assigned randomly to receive either a tablet cabergoline at dose 0.5 mg/wk or placebo for 4 months. Sixteen subjects (PCOS: n = 8; controls: n = 8) received whereas 13 n = 6; n = 7) placebo. Interventions Both before during 4th month treatment, blood samples were collected every 10 minutes from 9:00 A.M. 3:00 P.M., 3 7 days after spontaneous medroxyprogesterone acetate (MPA; 5 mg daily days)-induced menses. Follicle-stimulating hormone androgen levels measured basal samples, LH all samples. Main Outcome Measures Menstrual cyclicity, pulsatility, circulating FSH, PRL, E2, total T, free androstenedione, 17α-hydroxyprogesterone, DHEAS, sex hormone-binding globulin. Results controls PCOS-affected women, blunted plasma PRL without affecting pulsatility. Androgen reduced normalized PCOS. Cabergoline, but not placebo, induced menses reappearance amenorrheic normalization menstrual cyclicity oligoamenorrheic Conclusions The is capable normalize improve Cabergoline may represent an useful treatment irregularities patients.